VG Life Sciences, a leader in devising safe and effective therapies in a variety of infectious and inflammatory diseases, has announced that the Phase I study of the promising anti-cancer drug Pre-IND yielded positive results in stage 2 clinical trials. These clinical trials were conducted at Research Center of The University of Texas Health Science Center in San Antonio.
VG Life Sciences developed the active drug by utilizing metabolic disruption technology (MDT). The therapy is focused on managing or treating patients with a history of recurrent and relapsing solid tumors. The second cohort utilized a relatively higher dosage of hydroxychloroquine (HCQ) and sorafenib (marketed as Nexavar®) as compared to first cohort, and no significant side effects or toxicities were reported in any patient.
The research team of VG Life Sciences is very happy with the progress and results of clinical trial and Haig Keledjian (CEO of VG Life Sciences) has announced another follow up study:
“We have begun enrolling patients into the next dosing cohort in this dose-escalation study and look forward to reporting those results in a timely fashion. We anticipate patient recruitment to accelerate since opening up the enrollment criteria to include patients with breast, colon, lung, liver, pancreatic, and ovarian cancer, and look forward to an ultimate study completion date, from a safety standpoint, of third quarter 2013.”
The third cohort will also be conducted at Cancer Therapy & Research Center in San Antonio, Texas, like the previous two cohorts. Dr. Tyler Curiel, the principal investigator of the trial, commented that the safety profile of the patients is of paramount importance, and the primary goal of this trial is to devise and ascertain the maximally effective safe dosage and combinations of the anti- cancer drugs.
For more information about the VG Life Sciences and third cohort being held at Cancer Therapy & Research Center in San Antonio, Texa , visit www.VGLifeSciences.com.